Search

Your search keyword '"Kudo, Masatoshi"' showing total 4,766 results
Start Over Author "Kudo, Masatoshi"
4,766 results on '"Kudo, Masatoshi"'

102. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver–Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS

Author

Dietrich, Christoph F., Nolsøe, Christian Pállson, Barr, Richard G., Berzigotti, Annalisa, Burns, Peter N., Cantisani, Vito, Chammas, Maria Cristina, Chaubal, Nitin, Choi, Byung Ihn, Clevert, Dirk-André, Cui, Xinwu, Dong, Yi, D'Onofrio, Mirko, Fowlkes, J. Brian, Gilja, Odd Helge, Huang, Pintong, Ignee, Andre, Jenssen, Christian, Kono, Yuko, Kudo, Masatoshi, Lassau, Nathalie, Lee, Won Jae, Lee, Jae Young, Liang, Ping, Lim, Adrian, Lyshchik, Andrej, Meloni, Maria Franca, Correas, Jean Michel, Minami, Yasunori, Moriyasu, Fuminori, Nicolau, Carlos, Piscaglia, Fabio, Saftoiu, Adrian, Sidhu, Paul S., Sporea, Ioan, Torzilli, Guido, Xie, Xiaoyan, and Zheng, Rongqin

Published
2020
Full Text
View/download PDF

103. Histological diagnosis and grading of pancreatic neuroendocrine tumor by endoscopic ultrasound-guided fine needle biopsy using a 25-gauge needle with a core trap: A multicenter prospective trial

Author

Kamata, Ken, Ashida, Reiko, Yasukawa, Satoru, Chiba, Yasutaka, Fukutake, Nobuyasu, Nebiki, Hiroko, Kurita, Akira, Takaoka, Makoto, Ogura, Takeshi, Shiomi, Hideyuki, Asada, Masanori, Yasuda, Hiroaki, Shigekawa, Minoru, Yanagisawa, Akio, Kudo, Masatoshi, and Kitano, Masayuki

Published
2020
Full Text
View/download PDF

107. Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab.

Author

Rimini, Margherita, Stefanini, Bernardo, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Finkelmeier, Fabian, Yoo, Changhoon, Presa, José, Amadeo, Elisabeth, genovesi, Virginia, De Grandis, Maria Caterina, Iavarone, Massimo, Marra, Fabio, Foschi, Francesco, Tamburini, Emiliano, Rossari, Federico, Vitiello, Francesco, Bartalini, Linda, and Soldà, Caterina

Subjects
BODY mass index, ATEZOLIZUMAB, BEVACIZUMAB, PROGNOSIS, UNIVARIATE analysis
Abstract

Introduction: Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment. Methods and Material: The cohort included consecutive patients affected by BCLC‐c and BCLC‐B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first‐line therapy. Population was stratified according to the BMI in under‐, over‐ and normal‐weight according to the conventional thresholds. The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product‐limit method of Kaplan–Meier. The role of stratification factors was analysed with log‐rank tests. Results: 1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal‐weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal‐weight patients, whereas no differences were found between normal‐weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal‐weight patients (HR: 1.7; 95% CI: 1.0–2.8; p =.0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal‐weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal‐weight versus underweight and between normal‐weight versus overweight, which was confirmed at multivariate analysis. Conclusion: Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

108. Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.

Author

Aoki, Tomoko, Nishida, Naoshi, Kurebayashi, Yutaka, Sakai, Kazuko, Morita, Masahiro, Chishina, Hirokazu, Takita, Masahiro, Hagiwara, Satoru, Ida, Hiroshi, Ueshima, Kazuomi, Minami, Yasunori, Tsurusaki, Masakatsu, Nakai, Takuya, Sakamoto, Michiie, Nishio, Kazuto, and Kudo, Masatoshi

Subjects
WNT genes, CELL adhesion molecules, MYELOID-derived suppressor cells, REGULATORY T cells, TRANSCRIPTION factors, ADENOMATOUS polyposis coli, CD25 antigen, HEPATOCELLULAR carcinoma
Abstract

Introduction: Immunotherapy is becoming a promising approach for unresectable-hepatocellular carcinoma (HCC); the anti-tumor response is affected by the tumor microenvironment (TME). Although Wnt/β-catenin mutations are reported to cause non-inflamed phenotype, their role on TME remains controversial. We aimed to clarify the heterogeneity of immunophenotype in HCC with Wnt/β-catenin mutations. Methods: This study includes 152 resected HCCs; mutations in the catenin beta-1, adenomatous polyposis coli, or AXIN1, or AXIN2 genes were defined as Wnt/β-catenin mutations. With hierarchical cluster analyses, TME was classified into inflamed or non-inflamed classes based on the gene expressions associated with T-cell activation. Expression profiles of molecules related to cell differentiation and biliary-stem cell markers were compared between the TME classes to investigate whether differences in tumor traits were associated with TME. Results: Forty of 152 (26.3%) HCCs carried the Wnt/β-catenin mutations. Of these, 33 were classified as non-inflamed (33/40, 82.5%) and 7 as inflamed (7/40, 17.5%). Non-inflamed class was characterized by low number of CD3+, CD4+, and CD8+ cells on immunostaining, and high mRNA expressions of AXIN2 and GLUL, which are involved in the canonical Wnt/β-catenin signaling and hepatocyte differentiation, respectively. Non-inflamed tumors showed higher enhancement on the hepatobiliary-phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) compared to inflamed tumors. HCCs classified as inflamed class are revealed to have high numbers of CD3+, CD4+, and CD8+ tumor infiltrating lymphocytes on immunostaining. This class is associated with increased expression of anti-epithelial cell adhesion molecule and FOXM1 accompanied by upregulation of genes related to interferon-gamma signaling, dendritic cell migration, regulatory T cells, and myeloid-derived suppressor cell activation and recognized as low enhancement nodule on Gd-EOB-DTPA-enhanced MRI. Conclusion: Heterogeneity of tumor traits and TME was observed in HCC with Wnt/β-catenin mutation. The potential was indicated that tumor traits and TME are determined not only by the activation of the HNF4A but also by FOXM1, both of which are downstream transcription factor of the Wnt/β-catenin signaling pathway. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

109. Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma.

Author

Kudo, Masatoshi

Subjects
IMMUNE checkpoint inhibitors, KINASE inhibitors, CLINICAL trials, TUMOR antigens, CHEMOEMBOLIZATION, HEPATOCELLULAR carcinoma
Abstract

The text discusses the Phase 3 EMERALD-1 study, which found that combining durvalumab, bevacizumab, and transarterial chemoembolization (TACE) was more effective in treating unresectable hepatocellular carcinoma (HCC) compared to TACE alone. This combination therapy is the first to combine immunotherapy with an anti-VEGF agent and TACE for HCC, and it is considered a significant success. Other ongoing clinical trials are also investigating combination therapies for intermediate-stage and advanced-stage HCC, including the use of lenvatinib, pembrolizumab, tremelimumab, atezolizumab, and bevacizumab. The results of these trials may lead to triple therapy becoming the standard of care for certain HCC patients. [Extracted from the article]

Published
2024
Full Text
View/download PDF

110. Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study.

Author

Sim, Yu Ki, Chong, Ming Chuen, Gandhi, Mihir, Pokharkar, Yogesh Mahadev, Zhu, Yanan, Shi, Luming, Lequn, Li, Chen, Chien-Hung, Kudo, Masatoshi, Lee, Joon Hyeok, Strasser, Simone I., Chanwat, Rawisak, and Chow, Pierce K.H.

Subjects
HEPATOCELLULAR carcinoma, TREATMENT effectiveness, DIAGNOSIS, SPECTRUM allocation, HEPATITIS B, HEPATITIS C
Abstract

Introduction: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. While there has been rapid evolution in the treatment paradigm of HCC across the past decade, the extent to which these newly approved therapies are utilized in clinical practice in the real world is, however, unknown. The INSIGHT study was an investigator-initiated, multi-site longitudinal cohort study conducted to reflect real-world epidemiology and clinical practice in Asia-Pacific in the immediate 7-year period after the conclusion of the BRIDGE study. Methods: Data were collected both retrospectively (planned 30% of the total cohort size) and prospectively (planned 70%) from January 2013 to December 2019 from eligible patients newly diagnosed with HCC from 33 participating sites across 9 Asia-Pacific countries. Results: A total of 2,533 newly diagnosed HCC patients (1,052 in retrospective cohort and 1,481 in prospective cohort) were enrolled. The most common risk factor was hepatitis B in all countries except Japan, Australia, and New Zealand, where the prevalence of hepatitis C and diabetes were more common. The top three comorbidities reported in the INSIGHT study include cirrhosis, hypertension, and diabetes. We observe high heterogeneity in the first-line treatment recorded across countries and across disease stages, which significantly affects survival outcomes. Stratification by factors such as etiologies, tumor characteristics, the presence of extrahepatic metastases or macrovascular invasion, and the use of subsequent lines of treatment were performed. Conclusion: The INSIGHT study describes a wide spectrum of clinical management practices in HCC, where patient demographics, differential costs, and patient access to therapies may lead to wide geographical variations through the patient's treatment cycle, from diagnosis to clinical outcome. The high heterogeneity in patient outcomes demonstrates the need for more robust and clinical management strategies to be designed and adopted to bring about better patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

114. Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management

Author

Taouli, Bachir, primary, Ba-Ssalamah, Ahmed, additional, Chapiro, Julius, additional, Chhatwal, Jagpreet, additional, Fowler, Kathryn, additional, Kang, Tae Wook, additional, Knobloch, Gesine, additional, Koh, Dow-Mu, additional, Kudo, Masatoshi, additional, Lee, Jeong Min, additional, Murakami, Takamichi, additional, Pinato, David J., additional, Ringe, Kristina I., additional, Song, Bin, additional, Tabrizian, Parissa, additional, Wang, Jin, additional, Yoon, Jeong Hee, additional, Zeng, Mengsu, additional, Zhou, Jian, additional, and Vilgrain, Valérie, additional

Published
2023
Full Text
View/download PDF

115. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Llovet, Josep M, primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Masi, Gianluca, additional, Kwiatkowski, Mariusz, additional, Lim, Ho Yeong, additional, Kim, Jee Hyun, additional, Breder, Valeriy, additional, Kumada, Hiromitsu, additional, Cheng, Ann-Lii, additional, Galle, Peter R, additional, Kaneko, Shuichi, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dutcus, Corina, additional, Dubrovsky, Leonid, additional, Siegel, Abby B, additional, Finn, Richard S, additional, Strasser, Simone, additional, Thompson, Alexander, additional, Roohullah, Aflah, additional, Sievert, William, additional, Andelkovic, Vladimir, additional, Knox, Jennifer, additional, Davies, Janine, additional, Asselah, Jamil, additional, Brahmania, Mayur, additional, Majeed, Habeeb, additional, Villanueva, Luis, additional, Yanez Weber, Patricio, additional, Garrido, Marcelo, additional, Pizarro, Gonzalo Ignacio, additional, Yanez, Nicolas, additional, Ou, Shuangyan, additional, Pan, Hongming, additional, Meng, Zhiqiang, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Zhang, Tao, additional, Hao, Chunyi, additional, Cao, Peiguo, additional, Guo, Yabing, additional, Xiao, Juxiang, additional, Fang, Weijia, additional, Wang, Xin, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Yan, Dong, additional, Zhao, Hong, additional, Ying, Jieer, additional, Bonilla, Carlos, additional, Urrego, Olga, additional, Zambrano, Angela, additional, Lema, Mauricio, additional, Restrepo Gutierrez, Juan Carlos, additional, Cardona, Andres, additional, Franco Millan, Sandra, additional, Oscar, Madiedo, additional, Ramos, Victor, additional, LeSourd, Samuel, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Cattan, Stephane, additional, Bouattour, Mohamed, additional, Mineur, Laurent, additional, Regnault, Helene, additional, Dauvois, Barbara, additional, Schulze, Kornelius, additional, Folprecht, Gunnar, additional, Geier, Andreas, additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Venerito, Marino, additional, Berres, Marie-Luise, additional, Berg, Thomas, additional, Lange, Christian, additional, Schmidt, Hartmut, additional, Waldschmidt, Dirk T, additional, Bitzer, Michael, additional, McDermott, Ray, additional, Duffy, Austin, additional, Zagonel, Vittorina, additional, Tonini, Giuseppe, additional, Piscaglia, Fabio, additional, Gori, Stefania, additional, Rizzo, Mimma, additional, Biscaldi, Elisa, additional, Foltran, Luisa, additional, Cabibbo, Giuseppe, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Marusawa, Hiroyuki, additional, Kato, Naoya, additional, Kurosaki, Masayuki, additional, Morimoto, Manabu, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Masaki, Tsutomu, additional, Tateishi, Ryosuke, additional, Inaba, Yoshitaka, additional, Arakawa, Tomohiro, additional, Suzuki, Yoshiyuki, additional, Akua, Norio, additional, Kobayashi, Masahiro, additional, Hosaka, Tetsuya, additional, Nakamuta, Makoto, additional, Oza, Noriko, additional, Kondo, Shunsuke, additional, Furuse, Junji, additional, Nagashima, Fumio, additional, Kitano, Masayuki, additional, Takaguchi, Koichi, additional, Kim, Tae-You, additional, Kim, Han Sang, additional, Hernandez Hernandez, Carlos, additional, Motola Kuba, Daniel, additional, Segura Gonzalez, Manuel, additional, Cabrera Luviano, Jesus, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Silva-Bravo, Fernando, additional, Gane, Edward, additional, Stedman, Catherine, additional, Wyrwicz, Lucjan, additional, Nowakowska-Zajdel, Ewa, additional, Kraj, Leszek, additional, Janczewska, Ewa, additional, Surma-Wlodarczyk, Renata, additional, Sekacheva, Marina, additional, Orlova, Rashida, additional, Vasilyev, Alexander, additional, Zukov, Ruslan, additional, Vladimirov, Vladimir, additional, Minguez, Beatriz, additional, Matilla Pena, Ana, additional, Fernandez Castroagudin, Javier, additional, Romero Gomez, Manuel, additional, Luis Lledo, Jose, additional, Rubin, Angel, additional, Garcia Sanchez, Araceli, additional, Calleja Panero, Jose, additional, Yu, Ming-Chin, additional, Shen, Ying-Chun, additional, Huang, Yi-Hsiang, additional, Jeng, Long-Bin, additional, Chang, Ting-Tsung, additional, Yang, Sheng-Shun, additional, Chen, Shinn-Cherng, additional, Dechaphunkul, Arunee, additional, Tanwandee, Tawesak, additional, Leerapun, Apinya, additional, Seker, Mesut, additional, Harputluoglu, Hakan, additional, Cicin, Irfan, additional, Oksuzoglu, Berna, additional, Bilici, Mehmet, additional, Sezgin Goksu, Sema, additional, Artac, Mehmet, additional, Cil, Timucin, additional, Yalcin, Suayib, additional, Sarker, Debashis, additional, Rao, Ankit, additional, Palmer, Daniel, additional, Evans, Jeff, additional, Hubner, Richard, additional, Finn, Richard, additional, Ulahannan, Susanna, additional, Zakari, Ahmed, additional, Feun, Lynn, additional, Al-Rajabi, Raed, additional, Sung, Max, additional, He, Aiwu, additional, Kardosh, Adel, additional, Goyal, Lipika, additional, Li, Daneng, additional, Choi, Minsig, additional, Posada, Juan, additional, Dodlapati, Jyothi, additional, Shroff, Rachna, additional, Agrawal, Saurabh, additional, Gopaluni, Srivalli, additional, Akce, Mehmet, additional, Alese, Olatunji, additional, Baron, Ari, additional, Dunne, Richard, additional, Loaiza-Bonilla, Arturo, additional, and Frenette, Catherine, additional

Published
2023
Full Text
View/download PDF

116. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Author

Peyrin-Biroulet, Laurent, primary, Allegretti, Jessica R., additional, Rubin, David T., additional, Bressler, Brian, additional, Germinaro, Matthew, additional, Huang, Kuan-Hsiang (Gary), additional, Shipitofsky, Nicole, additional, Zhang, Hongyan, additional, Wilson, Rebbecca, additional, Han, Chenglong, additional, Feagan, Brian G., additional, Sandborn, William J., additional, Panés, Julian, additional, Hisamatsu, Tadakazu, additional, Lichtenstein, Gary R., additional, Sands, Bruce E., additional, Dignass, Axel, additional, Abrahamovych, Orest, additional, Afanasieva, Halyna, additional, Aitova, Lilia, additional, Altintas, Engin, additional, Altwegg, Romain, additional, Andreev, Pavel, additional, Aomatsu, Kazuki, additional, Augustyn, Monika, additional, Balestrieri, Paola, additional, Begun, Jakob, additional, Brunatto, Luciana, additional, Bulgheroni, Diego, additional, Bunkova, Elena, additional, Cabello, Mercedes, additional, Cao, Qian, additional, Caprioli, Flavio, additional, Cerqueira, Rute, additional, Chen, Baili, additional, Chen, Chou-Chen, additional, Chen, Chou-Pin, additional, Chiu, Cheng-Tang, additional, Choi, Chang Hwan, additional, Cicala, Michele, additional, Datsenko, Olena, additional, Dewint, Pieter, additional, Domenech, Eugeni, additional, Dutré, Joris, additional, Duvall, George, additional, Fernandez, Juan, additional, Filip, Rafal, additional, Fogel, Ronald, additional, Fowler, Sharyle, additional, Fujii, Toshimitsu, additional, Fukata, Masayuki, additional, Furumoto, Yohei, additional, Gasbarrini, Antonio, additional, Gawdis-Wojnarska, Beata, additional, Gilletta, Cyrielle, additional, Gionchetti, Paolo, additional, Goldin, Eran, additional, Golovchenko, Oleksandr, additional, Gonciarz, Maciej, additional, Gonen, Can, additional, Segura, Gaston Gonzalez, additional, Gridnyev, Oleksii, additional, Gyokeres, Tibor, additional, Hébuterne, Xavier, additional, Hedin, Charlotte, additional, Hellström, Per, additional, Hilmi, Ida Normiha, additional, Horný, Ivo, additional, Horvat, Gyula, additional, Hoshi, Namiko, additional, Hrdlicka, Ludek, additional, Ishihara, Shunji, additional, Ivanishyn, Olha, additional, Jang, Byung Ik, additional, Junior, Odery, additional, Kagaya, Takashi, additional, Kanmura, Shuji, additional, Karakina, Marina, additional, Katsuhiko, Nakai, additional, Kierkus, Jaroslaw, additional, Kim, Hyo Jong, additional, Kim, Tae-Oh, additional, Kim, Young-Ho, additional, Kiss, Gyula G., additional, Klaus, Jochen, additional, Kleczkowski, Dariusz, additional, Klopocka, Maria, additional, Kobayashi, Taku, additional, Kobielusz-Gembala, Iwona, additional, Koo, Ja Seol, additional, Kopon, Adam, additional, Kravchenko, Tetiana, additional, Kudo, Masatoshi, additional, Kwon, Kwang An, additional, Lago, Paula, additional, Laharie, David, additional, Lawrance, Ian, additional, Leszczyszyn, Jaroslaw, additional, Li, Yan, additional, Lukas, Milan, additional, Maaser, Christian, additional, Maemoto, Atsuo, additional, Marusawa, Hiroyuki, additional, McBride, Matthew, additional, Mendu, Shoba, additional, Miheller, Pal, additional, Miyabayashi, Hideharu, additional, Mohl, Wolfgang, additional, Moore, Gregory, additional, Motoya, Satoshi, additional, Murali, Narayanachar, additional, Naem, Mohammed, additional, Nakajima, Koichi, additional, Nakamoto, Yasunari, additional, Nancey, Stéphane, additional, Neto, Joaquim, additional, Onizawa, Michio, additional, Ono, Yohei, additional, Osada, Taro, additional, Osipenko, Marina, additional, Owczarek, Danuta, additional, Patel, Bhaktasharan, additional, Patel, Kamal, additional, Petrova, Elina, additional, Poroshina, Elena, additional, Portela, Francisco, additional, Prystupa, Lyudmyla, additional, Rivero, Monserrat, additional, Roblin, Xavier, additional, Romatowski, Jacek, additional, Rydzewska, Grazyna, additional, Saibeni, Simone, additional, Sakuraba, Hirotake, additional, Samaan, Mark, additional, Schultz, Michael, additional, Schulze, Joerg, additional, Sedghi, Shahriar, additional, Seidler, Ursula, additional, Shin, Sung Jae, additional, Stanislavchuk, Mykola, additional, Stokesberry, David, additional, Suzuki, Takayoshi, additional, Taguchi, Hiroki, additional, Tankova, Lyudmila, additional, Thin, Lena, additional, Tkachev, Alexander, additional, Torrealba, Leyanira, additional, Tsarynna, Nataliia, additional, Tulassay, Zsolt, additional, Ueo, Tetsuya, additional, Valuyskikh, Ekaterina, additional, Vasilevskaya, Olga, additional, Viamonte, Manuel, additional, Wei, Shu-Chen, additional, Weisshof, Roni, additional, Wojcik, Katarzyna, additional, Ye, Byong Duk, additional, Yen, Hsu-Heng, additional, Yoon, Hyuk, additional, Yoshida, Kosuke, additional, Yurkiv, Andriy, additional, Zaha, Osamu, additional, and Zhan, Qiang, additional

Published
2023
Full Text
View/download PDF

117. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, primary, Scheiner, Bernhard, additional, Maria Fulgenzi, Claudia Angela, additional, D’Alessio, Antonio, additional, Pomej, Katharina, additional, Roig, Marta Bofill, additional, Meyer, Elias Laurin, additional, Cheon, Jaekyung, additional, Nishida, Naoshi, additional, Lee, Pei-Chang, additional, Wu, Linda, additional, Ang, Celina, additional, Krall, Anja, additional, Saeed, Anwaar, additional, Stefanini, Bernardo, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Abugabal, Yehia I., additional, Chamseddine, Shadi, additional, Wietharn, Brooke, additional, Parisi, Alessandro, additional, Huang, Yi-Hsiang, additional, Phen, Samuel, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Silletta, Marianna, additional, Trauner, Michael, additional, Samson, Adel, additional, Wege, Henning, additional, Piscaglia, Fabio, additional, Galle, Peter R., additional, Stauber, Rudolf, additional, Kudo, Masatoshi, additional, Singal, Amit G., additional, Itani, Aleena, additional, Ulahannan, Susanna V., additional, Parikh, Neehar D., additional, Cortellini, Alessio, additional, Kaseb, Ahmed, additional, Rimassa, Lorenza, additional, Chon, Hong Jae, additional, Pinato, David J., additional, and Pinter, Matthias, additional

Published
2023
Full Text
View/download PDF

119. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study

Author

Kudo, Masatoshi, primary, Tsuchiya, Kaoru, additional, Shao, Yu-Yun, additional, Finn, Richard S., additional, Galle, Peter R., additional, Ducreux, Michel, additional, Cheng, Ann-Lii, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Take, Ryosuke, additional, Yamada, Kyoko, additional, Asakawa, Takashi, additional, Nakagawa, Yuki, additional, and Ikeda, Masafumi, additional

Published
2023
Full Text
View/download PDF

120. α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Burgio, Valentina, additional, Piscaglia, Fabio, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei‐Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2023
Full Text
View/download PDF

122. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

Author

Dharmapuri, Sirish, primary, Özbek, Umut, additional, Jethra, Hiren, additional, Jun, Tomi, additional, Marron, Thomas U, additional, Saeed, Anwaar, additional, Huang, Yi-Hsiang, additional, Muzaffar, Mahvish, additional, Pinter, Matthias, additional, Balcar, Lorenz, additional, Fulgenzi, Claudia, additional, Amara, Suneetha, additional, Weinmann, Arndt, additional, Personeni, Nicola, additional, Scheiner, Bernhard, additional, Pressiani, Tiziana, additional, Navaid, Musharraf, additional, Bengsch, Bertram, additional, Paul, Sonal, additional, Khan, Uqba, additional, Bettinger, Dominik, additional, Nishida, Naoshi, additional, Mohamed, Yehia Ibrahim, additional, Vogel, Arndt, additional, Gampa, Anuhya, additional, Korolewicz, James, additional, Cammarota, Antonella, additional, Kaseb, Ahmed, additional, Galle, Peter R, additional, Pillai, Anjana, additional, Wang, Ying-Hong, additional, Cortellini, Alessio, additional, Kudo, Masatoshi, additional, D’Alessio, Antonio, additional, Rimassa, Lorenza, additional, Pinato, David James, additional, and Ang, Celina, additional

Published
2023
Full Text
View/download PDF

123. A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

Author

Kudo, Masatoshi, primary, Finn, Richard S., additional, Ikeda, Masafumi, additional, Sung, Max W., additional, Baron, Ari D., additional, Okusaka, Takuji, additional, Kobayashi, Masahiro, additional, Kumada, Hiromitsu, additional, Kaneko, Shuichi, additional, Pracht, Marc, additional, Meyer, Tim, additional, Nagao, Satoshi, additional, Saito, Kenichi, additional, Mody, Kalgi, additional, Ramji, Zahra, additional, Dubrovsky, Leonid, additional, and Llovet, Josep M., additional

Published
2023
Full Text
View/download PDF

124. Correction: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion

Author

Taouli, Bachir, primary, Ba-Ssalamah, Ahmed, additional, Chapiro, Julius, additional, Chhatwal, Jagpreet, additional, Fowler, Kathryn, additional, Kang, Tae Wook, additional, Knobloch, Gesine, additional, Koh, Dow-Mu, additional, Kudo, Masatoshi, additional, Lee, Jeong Min, additional, Murakami, Takamichi, additional, Pinato, David J., additional, Ringe, Kristina I., additional, Song, Bin, additional, Tabrizian, Parissa, additional, Wang, Jin, additional, Yoon, Jeong Hee, additional, Zeng, Mengsu, additional, Zhou, Jian, additional, and Vilgrain, Valérie, additional

Published
2023
Full Text
View/download PDF

125. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies

Author

Piratvisuth, Teerha, primary, Hou, Jinlin, additional, Tanwandee, Tawesak, additional, Berg, Thomas, additional, Vogel, Arndt, additional, Trojan, Jörg, additional, De Toni, Enrico N., additional, Kudo, Masatoshi, additional, Eiblmaier, Anja, additional, Klein, Hanns-Georg, additional, Hegel, Johannes Kolja, additional, Madin, Kairat, additional, Kroeniger, Konstantin, additional, Sharma, Ashish, additional, and Chan, Henry L.Y., additional

Published
2023
Full Text
View/download PDF

127. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Qin, Shukui, primary, Chen, Minshan, additional, Cheng, Ann-Lii, additional, Kaseb, Ahmed O, additional, Kudo, Masatoshi, additional, Lee, Han Chu, additional, Yopp, Adam C, additional, Zhou, Jian, additional, Wang, Lu, additional, Wen, Xiaoyu, additional, Heo, Jeong, additional, Tak, Won Young, additional, Nakamura, Shinichiro, additional, Numata, Kazushi, additional, Uguen, Thomas, additional, Hsiehchen, David, additional, Cha, Edward, additional, Hack, Stephen P, additional, Lian, Qinshu, additional, Ma, Ning, additional, Spahn, Jessica H, additional, Wang, Yulei, additional, Wu, Chun, additional, Chow, Pierce K H, additional, Thompson, Alexander, additional, Danta, Mark, additional, Poursoltan, Pirooz, additional, Kiberu, Andrew, additional, Chittajallu, Renuka, additional, Sood, Siddarth, additional, Stauber, Rudolf, additional, Pinter, Matthias, additional, Peck-Radosavljevic, Markus, additional, Decaestecker, Jochen, additional, Cuyle, Pieter-Jan, additional, Verset, Gontran, additional, Van Vlierberghe, Hans, additional, De Azevedo, Sergio, additional, Andrade, Livia, additional, Cunha Júnior, Ademar, additional, Faria, Luiza, additional, Yen, Cheng Tzu, additional, Colli, Leandro, additional, Asselah, Jamil, additional, Kavan, Petr, additional, Marquez, Vladimir, additional, Brahmania, Mayur, additional, Li, Qiang, additional, Xing, Baocai, additional, Guo, Yabing, additional, Chen, Zhendong, additional, Zhao, Haitao, additional, Peng, Tao, additional, Wang, Liming, additional, Liu, Hongming, additional, Wu, Feixiang, additional, Qin, Lunxiu, additional, Zheng, Qichang, additional, Ying, Jieer, additional, Li, Haitao, additional, Wen, Tianfu, additional, Qin, Shukui, additional, Liu, Yunpeng, additional, Wang, Boqing, additional, Bai, Yuxian, additional, He, Yifu, additional, Zhao, Hong, additional, Zhou, Dong, additional, Dai, Chaoliu, additional, Teng, Gaojun, additional, Cui, Shuzhong, additional, Gao, Yi, additional, Zhang, Xizhi, additional, Lu, Zheng, additional, Yin, Tao, additional, Ding, Youming, additional, Jia, Weidong, additional, Xia, Yongxiang, additional, Sun, Beicheng, additional, Xia, Qiang, additional, Yuan, Yufeng, additional, Sun, Huichuan, additional, Shi, Xuetao, additional, Guzmán, Adrián, additional, Corrales, Luis, additional, Kral, Zdenek, additional, Priester, Peter, additional, Kubala, Eugen, additional, Blanc, Jean Frederic, additional, Bourliere, Marc, additional, Peron, Jean Marie, additional, Borg, Christophe, additional, Bronowicki, Jean-Pierre, additional, Ganne, Nathalie, additional, Decaens, Thomas, additional, Heurgue, Alexandra, additional, Trojan, Joerg, additional, Gonzalez-Carmona, Maria Angeles, additional, Roderburg, Christoph, additional, Ettrich, Thomas, additional, Schotten, Clemens, additional, Kandulski, Arne, additional, Yau, Thomas, additional, Chan, Lam, additional, Scartozzi, Mario, additional, Masi, Gianluca, additional, Fanello, Silvia, additional, Battezzati, Pier Maria, additional, Leonardi, Francesco, additional, Ghidini, Michele, additional, Morimoto, Manabu, additional, Hidaka, Hisashi, additional, Tsuchiya, Kaoru, additional, Yamashita, Tatsuya, additional, Kato, Naoya, additional, Hagihara, Atsushi, additional, Koga, Hironori, additional, Arakawa, Tomohiro, additional, Nakamura, Ikuo, additional, Kawamura, Yusuke, additional, Kawaoka, Tomokazu, additional, Shimada, Mitsuo, additional, Hasegawa, Kiyoshi, additional, Marusawa, Hiroyuki, additional, Nakamura, Shinchiro, additional, Hiraoka, Atsushi, additional, Hayashi, Hiromitsu, additional, Takeda, Shin, additional, Paik, Seung Woon, additional, Kim, Do Young, additional, Lee, Jung Il, additional, Jeong, Sook-Hyang, additional, Kim, Won, additional, Kim, Hyeyeong, additional, Chon, Hong Jae, additional, Cheong, Jaeyoun, additional, Yoon, Seung Kew, additional, Yoon, Jung-Hwan, additional, Villalobos, Ricardo, additional, Martinez Rodriguez, Jorge Luis, additional, Oyervides Juarez, Victor, additional, Hernández, Carlos Alberto, additional, Klumpen, Heinz-Josef, additional, de Vos-Geelen, Judith, additional, Gane, Edward, additional, Montenegro, Paola, additional, Torres Mattos, Cesar, additional, Janczewska, Ewa, additional, Kawecki, Maciej, additional, Nowakowska-Zajdel, Ewa, additional, Fedenko, Alexander, additional, Granov, Dmitrii, additional, Alyasova, Anna, additional, Sekacheva, Marina, additional, Ledin, Evgeny, additional, Samol, Jens, additional, Toh, Han Chong, additional, Calvo Campos, Mariona, additional, Gomez Martin, Carlos, additional, Lopez Lopez, Carlos, additional, Muñoz Martin, Andres Jesus, additional, Calleja Panero, Jose Luis, additional, Montero Alvarez, Jose Luis, additional, Reig Monzón, Maria, additional, Delgado Mingorance, Ignacio, additional, Minguez Rosique, Beatriz, additional, Cheng, Ann Lii, additional, Huang, Yi-Hsiang, additional, Lin, Shi-Ming, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Su, Wei-Wen, additional, Korphaisarn, Krittiya, additional, Maneenil, Kunlatida, additional, Samdaengpan, Chayanee, additional, Tharavichitkul, Ekkapong, additional, Ozguroglu, Mustafa, additional, Kose, Fatih, additional, Harputluoglu, Hakan, additional, Buchschacher, Gary, additional, Thuluvath, Paul, additional, Xiong, Henry, additional, Patel, Mital, additional, Gold, Philip, additional, Li, Daneng, additional, Brooks, Gabriel, additional, Masood, Ashiq, additional, Patel, Reema, additional, George, Ben, additional, Salgia, Reena, additional, Manji, Gulam, additional, Crow, Mary, additional, Kaseb, Ahmed, additional, Dugan, Matthew, additional, Kadakia, Kunal, additional, Kardosh, Adel, additional, Gibbs, John, additional, Shah, Ashesh, additional, and Burris III, Howard, additional

Published
2023
Full Text
View/download PDF

128. Fontan術後に発症した切除不能肝細胞癌の1例

Author

Hagiwara, Satoru, primary, Ueshima, Kazuomi, additional, Nishida, Naoshi, additional, Ida, Hiroshi, additional, Minaga, Kosuke, additional, Minami, Yasunori, additional, Takita, Masahiro, additional, Aoki, Tomoko, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Matsubara, Takuya, additional, Omaru, Naoya, additional, Inamura, Noboru, additional, and Kudo, Masatoshi, additional

Published
2023
Full Text
View/download PDF

130. Two distinct characteristics of immune microenvironment in human hepatocellular carcinoma with Wnt/β-catenin mutations

Author

Aoki, Tomoko, primary, Nishida, Naoshi, additional, Kurebayashi, Yutaka, additional, Sakai, Kazuko, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Takita, Masahiro, additional, Hagiwara, Satoru, additional, Ida, Hiroshi, additional, Ueshima, Kazuomi, additional, Minami, Yasunori, additional, Tsurusaki, Masakatsu, additional, Nakai, Takuya, additional, Sakamoto, Michiie, additional, Nishio, Kazuto, additional, and Kudo, Masatoshi, additional

Published
2023
Full Text
View/download PDF

131. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Author

Qin, Shukui, primary, Kudo, Masatoshi, additional, Meyer, Tim, additional, Bai, Yuxian, additional, Guo, Yabing, additional, Meng, Zhiqiang, additional, Satoh, Taroh, additional, Marino, Donatella, additional, Assenat, Eric, additional, Li, Songzi, additional, Chen, Yaxi, additional, Boisserie, Frederic, additional, Abdrashitov, Ramil, additional, Finn, Richard S., additional, Vogel, Arndt, additional, and Zhu, Andrew X., additional

Published
2023
Full Text
View/download PDF

132. Real-World Data on Short-Term and Long-Term Treatment Results of Ustekinumab in Patients with Steroid-Resistant/Dependent Ulcerative Colitis

Author

Komeda, Yoriaki, primary, Tribonias, George, additional, Kono, Masashi, additional, Handa, Kohei, additional, Omoto, Shunsuke, additional, Takenaka, Mamoru, additional, Hagiwara, Satoru, additional, Tsuji, Naoko, additional, Nishida, Naoshi, additional, Kashida, Hiroshi, additional, and Kudo, Masatoshi, additional

Published
2023
Full Text
View/download PDF

135. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma

Author

Xie, Enrui, primary, Yeo, Yee Hui, additional, Scheiner, Bernhard, additional, Zhang, Yue, additional, Hiraoka, Atsushi, additional, Tantai, Xinxing, additional, Fessas, Petros, additional, de Castro, Tiago, additional, D’Alessio, Antonio, additional, Fulgenzi, Claudia Angela Maria, additional, Xu, Shuo, additional, Tsai, Hong-Ming, additional, Kambhampati, Swetha, additional, Wang, Wenjun, additional, Keenan, Bridget P., additional, Gao, Xu, additional, Xing, Zixuan, additional, Pinter, Matthias, additional, Lin, Yih-Jyh, additional, Guo, Zhanjun, additional, Vogel, Arndt, additional, Tanaka, Takaaki, additional, Kuo, Hsin-Yu, additional, Kelley, Robin K., additional, Kudo, Masatoshi, additional, Yang, Ju Dong, additional, Pinato, David J., additional, and Ji, Fanpu, additional

Published
2023
Full Text
View/download PDF

139. Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease

Author

Hagiwara, Satoru, Watanabe, Tomohiro, Kudo, Masatoshi, Minaga, Kosuke, Komeda, Yoriaki, Kamata, Ken, Kimura, Masatomo, Hayashi, Hidetoshi, Nakagawa, Kazuhiko, Ueshima, Kazuomi, Minami, Yasunori, Aoki, Tomoko, Takita, Masahiro, Morita, Masahiro, Cishina, Hirokazu, Ida, Hiroshi, Park, Ah-Mee, and Nishida, Naoshi

Published
2021
Full Text
View/download PDF

140. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

Author

Suzuki, Fumitaka, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Tanaka, Yasuhito, Kurosaki, Masayuki, Yatsuhashi, Hiroshi, Atarashi, Tomofumi, Atsukawa, Masanori, Watanabe, Tsunamasa, Enomoto, Masaru, Kudo, Masatoshi, Maeda, Naoto, Kohno, Hiroshi, Joko, Kouji, Michitaka, Kojiro, Miki, Koichiro, Takahashi, Kazuhiro, Ide, Tatsuya, Fujiyama, Shigetoshi, Kohno, Tomoko, Itoh, Hiroshi, Tsukamoto, Sakiyo, Suzuki, Yuko, Kawano, Yoshiaki, Sugiura, Wataru, and Kumada, Hiromitsu

Published
2021
Full Text
View/download PDF

145. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

Author

Kudo, Masatoshi, Okusaka, Takuji, Motomura, Kenta, Ohno, Izumi, Morimoto, Manabu, Seo, Satoru, Wada, Yoshiyuki, Sato, Shinpei, Yamashita, Tatsuya, Furukawa, Masayuki, Aramaki, Takeshi, Nadano, Seijin, Ohkawa, Kazuyoshi, Fujii, Hirofumi, Kudo, Toshihiro, Furuse, Junji, Takai, Hiroki, Homma, Gosuke, Yoshikawa, Reigetsu, and Zhu, Andrew X.

Published
2020
Full Text
View/download PDF

149. Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven method) in patients with surgically altered gastrointestinal anatomy (with video)

Author

Takenaka, Mamoru, Minaga, Kosuke, Kamata, Ken, Yamao, Kentaro, Yoshikawa, Tomoe, Ishikawa, Rei, Okamoto, Ayana, Yamazaki, Tomohiro, Nakai, Atsushi, Omoto, Shunsuke, Komeda, Yoriaki, Sakurai, Toshiharu, Watanabe, Tomohiro, Nishida, Naoshi, Chiba, Yasutaka, Kwon, Chang-Il, Jeong, Seok, Lee, Tae Hoon, and Kudo, Masatoshi

Published
2020
Full Text
View/download PDF

150. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Author

Yamashita, Tatsuya, Kudo, Masatoshi, Ikeda, Kenji, Izumi, Namiki, Tateishi, Ryosuke, Ikeda, Masafumi, Aikata, Hiroshi, Kawaguchi, Yasunori, Wada, Yoshiyuki, Numata, Kazushi, Inaba, Yoshitaka, Kuromatsu, Ryoko, Kobayashi, Masahiro, Okusaka, Takuji, Tamai, Toshiyuki, Kitamura, Chifumi, Saito, Kenichi, Haruna, Katsuya, Okita, Kiwamu, and Kumada, Hiromitsu

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results